To examine the clinical association between CREBBP/EP300 mutation—and other mutations in HNSCC—with radioresponse, we identified a cohort of patients within the Head and Neck Cancer Genome Atlas (TCGA) that were denoted as having radiation as a component of their therapy (Supplementary Table 4). The gene discussed is EP300; the disease is head and neck squamous cell carcinoma.